TGF-ß Signaling and Resistance to Cancer Therapy.
Front Cell Dev Biol
; 9: 786728, 2021.
Article
en En
| MEDLINE
| ID: mdl-34917620
The transforming growth factor ß (TGF-ß) pathway, which is well studied for its ability to inhibit cell proliferation in early stages of tumorigenesis while promoting epithelial-mesenchymal transition and invasion in advanced cancer, is considered to act as a double-edged sword in cancer. Multiple inhibitors have been developed to target TGF-ß signaling, but results from clinical trials were inconsistent, suggesting that the functions of TGF-ß in human cancers are not yet fully explored. Multiple drug resistance is a major challenge in cancer therapy; emerging evidence indicates that TGF-ß signaling may be a key factor in cancer resistance to chemotherapy, targeted therapy and immunotherapy. Finally, combining anti-TGF-ß therapy with other cancer therapy is an attractive venue to be explored for the treatment of therapy-resistant cancer.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Front Cell Dev Biol
Año:
2021
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Suiza